Company Information
CIN
Status
Date of Incorporation
29 March 2007
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
04 August 2023
Paid Up Capital
132,312,000
Authorised Capital
150,000,000
Directors
Zahabiya Habil Khorakiwala
Director/Designated Partner
almost 2 years ago
almost 2 years ago
Harsh Vardhan Goenka
Director/Designated Partner
about 2 years ago
about 2 years ago
Rajesh Ramesh Shirambekar
Director/Designated Partner
about 2 years ago
about 2 years ago
Rajat Bhargava
Director/Designated Partner
over 2 years ago
over 2 years ago
Lalit Surajmal Kanodia
Director/Designated Partner
over 3 years ago
over 3 years ago
Bhaskar Vemban Iyer
Director/Designated Partner
over 5 years ago
over 5 years ago
Sachin Rajkumar Nandgaonkar
Director/Designated Partner
over 5 years ago
over 5 years ago
Manojkumar Madangopal Maheshwari
Director/Designated Partner
about 6 years ago
about 6 years ago
Narendra Kumar Anand Ambwani
Director/Designated Partner
about 6 years ago
about 6 years ago
Yugal Kishor Chothuram Sikri
Director/Designated Partner
about 7 years ago
about 7 years ago
Neera Saggi .
Director
over 10 years ago
over 10 years ago
Niraj Ramkrishna Bajaj
Director
over 17 years ago
over 17 years ago
Past Directors
Chidambaram Renganathan
Managing Director
almost 11 years ago
almost 11 years ago
Rajendra Ambalal Shah
Alternate Director
over 13 years ago
over 13 years ago
Vinayaraghavan Corattiyil
Director Appointed In Casual Vacancy
over 13 years ago
over 13 years ago
Ajit Singh Chouhan
Managing Director
over 15 years ago
over 15 years ago
Chhaganlal Jain
Director
over 17 years ago
over 17 years ago
Dilip Kumar Sen
Director
over 17 years ago
over 17 years ago
Pradipta Kumar Mohapatra
Director
over 17 years ago
over 17 years ago
Arvind Vasudeva
Additional Director
almost 18 years ago
almost 18 years ago
Ajit Gulabchand
Additional Director
almost 18 years ago
almost 18 years ago
Mahesh Shrikrishna Gupta
Additional Director
almost 18 years ago
almost 18 years ago
Rajiv Ramchandra Dalvi
Director
over 18 years ago
over 18 years ago
Mortu Vishwanath Lotlikar
Director
over 18 years ago
over 18 years ago
Srinivas Gollamudi
Director
over 18 years ago
over 18 years ago
Patents
The present invention relates to a drug delivery solid dosage formulation of Sirolimus having improved in-vitro dissolution and in-vivo bioavailability, wherein Sirolimus is surface treated with a complexing agent and wetting agent in dissolved state, and to its method for preparation.
A mouth dissolvable and meltable, and water dispersable delivery system for oral administration consisting of an antipileptic drug, one or more swelling agents, one or more of fillers, one or more of disintegrating agents, and one or more of binders is disclosed. The swelling agent is powdered cellulose, filler is s...
A mouth dissolvable and meltable, and water dispersable delivery system for oral administration consisting of an antiepileptic drug, one or more swelling agent, one or more of disintegrating agents, and one or more of binders is disclosed. The swelling agent is powdered cellulose, filler is spray dried mannitol, dis...
A selfemulsifiable formulation comprising of lipophilic system consisting of medium chain triglyceride of caprylic acid and capric acid, and of labrasol, wherein labrasol also serves as surfactant, which is combined with other selected surfactants, like cremophore RH 40 and/or polysorbate 80 is disclosed, wherein sa...
Present invention provides a high yielding, safe and industrially feasible process for the preparation of benzazepine derivative. The dehalogenated side product 5-hydroxy-l-[2-methyi-4-(2-methylbenzoylamino) benzoyl]-2,3,4,5-tetrahydro-lH-1-benzazipine generation in this process is less than 0.1% by weight.
...
Amouth dissolvable and meltable, and water dispersable delivery system for oral administration consisting of an antiepileptic drug, one or more swelling agents one or more of fillers one or more of disintegrating agents and one or more of binders is disclosed. The swelling agent is powdered cellulose filler is spray...
The present invention relates to the process of pantoprazole sodium sesquihydrate Form I having following Formula –I. from pantoprazole sodium comprising formation of a suspension of pantoprazole sodium in a solvent mixture and directly recovering the pantoprazole sodium sesquihydrate Form-I by filtration.
...
A process for preparation of methyl-(+)-(S)-alpha-(2-chlorophenyl) –6,7-dihydrothieno [3,2-c] pyridine-5 (4H)-acetic acid methyl ester or salts thereof [clopidogrel or salts thereof of Formula –I] having higher chiral purity and products thereof is provided. A process for purification of the compound prepared is al...
The present invention relates to process for preparation of crystalline Form I of clopidogrel bisulfate comprising steps of preparing clear solution of clopidogrel free base in ethyl acetate, which is cooled to a temperature varying from about -7 to about -10°C and reacted with concentrated sulphuric acid white main...
The present invention relates to a pharmaceutical formulation having increased in-vitro dissolution, and reduced and controlled degradation under moisture and heat conditions comprising alpha ketoanalogue of amino acids and additional amino acids as active ingredients, and disintegrant, filler and binder, and coated...
Present invention provides a novel process for the preparation of 7 -Chloro-5-oxo-l-(2-methyl-4-Amino benzoyl) -2,3,4,5-tetrahydro-lH-benzazepine. This process is industrially feasible and scalable. The process does not make use of expensive, hazardous reagents and special equipment"s making it industrially feasible...
A process for the preparation of anti-psychotic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1 -piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[l,2,-a]pyrimidin-4-one, commonly known as risperidone of the formula I:Formula I comprising condensation of 3-substituted ethyl-6,7,8,9-tetrahydro-2-me...
The present invention rebates to antidiabetic compounds, and more particularly to derivatives of antidiabetic compounds belonging to the class of thiazolidinediones (TZDs), its bioisosieres i.e. a-substituted carboxylic acids and isoxazolidine-3, 5-diones, processes Vor their preparation, and their use as po...
Disclosed is an improved process for the preparation of cinacalcet hydrochloride of
formula
using key intermediate, sodium {1- hydroxy - 3-(3-trifluoromethyl phenyl) propyl}
sulfonate (Bisulphite adduct) (IIIa).
A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine of the formula I:c r Formula I commonly known as lamotrigine which comprises :a) reduction of 2,3'dichloronitrobenzene of the formula IX Formula IX in Ci -Ce aliphatic alkanol with hydr...
Disclosed is a process for the preparation of Solifenacin succinate of formula (I) by reacting of racemic (RS)-ethyl 1-phenyl-1, 2, 3, 4-tetrahydro-2-isoquinoline carboxylate with racemic (RS)-3-quinuclidinol followed by separation of (1S, 3R)-isomer from a mixture of four stereoisomers.
Registered Trademarks
[Class : 5] Medicinal And Pharmaceutical Preparations.
[Class : 5] Medicinal And Pharmaceutical Preparations.
[Class : 5] Medicinal And Pharmaceutical Preparations.
View +260 more Brands for Rpg Life Sciences Limited.
Charges
12 April 2017
Icici Bank Limited
20 Crore
12 September 2009
Union Bank Of India
65 Crore
28 January 2011
Export-import Bank Of India
7 Crore
09 April 2009
Export-import Bank Of India
20 Crore
25 January 2012
Export Import Bank Of India
7 Crore
08 March 2008
Export-import Bank Of India
4 Crore
14 July 2010
Export Import Bank Of India
3 Crore
12 January 2009
Export-import Bank Of India
4 Crore
21 June 2010
Union Bank Of India
4 Crore
19 March 2008
Union Bank Of India
75 Lak
12 April 2017
Others
0
12 September 2009
Others
0
19 March 2008
Union Bank Of India
0
09 April 2009
Export-import Bank Of India
0
25 January 2012
Export Import Bank Of India
0
08 March 2008
Export-import Bank Of India
0
28 January 2011
Export-import Bank Of India
0
14 July 2010
Export Import Bank Of India
0
21 June 2010
Union Bank Of India
0
12 January 2009
Export-import Bank Of India
0
12 April 2017
Others
0
12 September 2009
Others
0
19 March 2008
Union Bank Of India
0
09 April 2009
Export-import Bank Of India
0
25 January 2012
Export Import Bank Of India
0
08 March 2008
Export-import Bank Of India
0
28 January 2011
Export-import Bank Of India
0
14 July 2010
Export Import Bank Of India
0
21 June 2010
Union Bank Of India
0
12 January 2009
Export-import Bank Of India
0
12 April 2017
Others
0
12 September 2009
Others
0
19 March 2008
Union Bank Of India
0
09 April 2009
Export-import Bank Of India
0
25 January 2012
Export Import Bank Of India
0
08 March 2008
Export-import Bank Of India
0
28 January 2011
Export-import Bank Of India
0
14 July 2010
Export Import Bank Of India
0
21 June 2010
Union Bank Of India
0
12 January 2009
Export-import Bank Of India
0
Documents
Form MGT-7-05022021_signed
Form CHG-4-22102020_signed
Letter of the charge holder stating that the amount has been satisfied-21102020
Form DPT-3-20102020-signed
Form MSME FORM I-15102020_signed
Form MGT-14-02102020_signed
Copy of MGT-8-29092020
List of share holders, debenture holders;-29092020
Optional Attachment-(2)-29092020
Optional Attachment-(1)-29092020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-29092020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-08092020
Form AOC-4(XBRL)-08092020_signed
Form MGT-15-04092020_signed
Form DIR-12-04092020_signed
Optional Attachment-(1)-03092020
Optional Attachment-(1)-03092020
Notice of resignation;-24082020
Optional Attachment-(1)-24082020
Evidence of cessation;-24082020
Form DIR-12-24082020_signed
Declaration of the appointee director, Managing director, in Form No. DIR-2;-24082020
Form DPT-3-10082020-signed
Optional Attachment-(1)-03082020
Auditor?s certificate-03082020
Form MSME FORM I-29072020_signed
Form BEN - 2-02012020_signed
Form BEN - 2-27122019_signed
Optional Attachment-(1)-27122019
Declaration under section 90-27122019
